COMP <GO>
TARS vs ADPT // REVENUE GROWTH (YOY)
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Adaptive Biotechnologies Corporation (NASDAQ) • 15-METRIC TALLY: TARS 6
— ADPT 3
▲ REVENUE GROWTH (YOY) LEADER: TARS
LAST: $72.64 (-0.93%) • MKT CAP: $3.61B
revenue-growth
146.70%
LAST: $25.80 (+2.95%) • MKT CAP: $4.00B
revenue-growth
54.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. ADPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | ADPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | -12.50% | -11.60 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | -1.09% | +0.48 | TARS | /fcf-yield <GO> |
| Operating Margin | -15.70% | -20.60% | +4.90 | TARS | /operating-margins <GO> |
| Net Profit Margin | -14.60% | -21.50% | +6.90 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 146.70% | 54.80% | +91.90 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | 6.32 | +3.87 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.9 | 43.7 | +7.20 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.01 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.61B | $4.00B | -$384.5M | ADPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | ADPT REV | TARS GROSS % | ADPT GROSS % | TARS FCF | ADPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $277.0M | — | 74.2% | -$22.3M | -$48.9M |
| FY 2024 | $183.0M | $179.0M | — | 59.7% | -$84.6M | -$98.9M |
| FY 2023 | $17.4M | $170.3M | — | — | -$117.5M | -$164.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
ADPT // BETA 1.01